Karyopharm stock drops af­ter in­hibitor's PhI da­ta show low­er dose not as ef­fec­tive: #AACR23

Karyopharm Ther­a­peu­tics shared up­dat­ed Phase I da­ta for its oral XPO1 in­hibitor, which is be­ing test­ed as a treat­ment for myelofi­bro­sis in com­bi­na­tion with rux­oli­tinib, that found a high­er dose of the com­bi­na­tion ther­a­py im­proved symp­toms in 80% of pa­tients.

The news was an­nounced Tues­day at the Amer­i­can As­so­ci­a­tion for Can­cer Re­search, and Karyopharm’s stock $KP­TI was down about 3% in trad­ing on Wednes­day af­ter­noon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER